Business
Gunze Medical and HistoSonics Enter into Exclusive Distributor Agreement in Japan for Noninvasive Platform and Proprietary Sonic Beam Therapy Using Histotripsy Technology
OSAKA, Japan, October 08, 2025--Gunze Limited (Headquarters: Osaka, Japan; President: Toshiyasu Saguchi) [TOKYO:3002] is pleased to announce that its wholly owned subsidiary, Gunze Medical Limited (Headquarters: Osaka, Japan; President: Shojiro Matsuda) and HistoSonics, Inc. (Headquarters: Minneapolis, MN USA; CEO: Mike Blue) have entered into an agreement to exclusively distribute a noninvasive platform and proprietary sonic beam therapy utilizing the histotripsy technology.Under this agreement
About this update from Gunze Limited
OSAKA, Japan, October 08, 2025--(BUSINESS WIRE)--Gunze Limited (Headquarters: Osaka, Japan; President: Toshiyasu Saguchi) [TOKYO:3002] is pleased to announce that its wholly owned subsidiary, Gunze Medical Limited (Headquarters: Osaka, Japan; President: Shojiro Matsuda) and HistoSonics, Inc. (Headquarters: Minneapolis, MN USA; CEO: Mike Blue) have entered into an agreement to exclusively distribute a noninvasive platform and proprietary sonic beam therapy utilizing the histotripsy technology.Under this agreement, Gunze Medical will assume exclusive distribution responsibility in Japan for non-invasive ultrasound therapy devices equipped with Histotripsy technology developed by HistoSonics. Moving forward, the company will work to obtain manufacturing and marketing approval and insurance coverage in Japan, while also establishing a support and training system in collaboration with medical institutions. This will contribute to reducing the physical burden on patients through more accurate treatment and improving efficiency and quality in medical settings. About noninvasive histotripsy platform This medical device uses histotripsy technology, the world's first noninvasive treatment method that utilizes microbubbles generated by ultrasound. Histotripsy is a novel technology that uses ultrasound energy to physically disrupt cancerous tissue without the need for surgical intervention. Focusing ultrasound at a single point creates a cluster of microbubbles called a "bubble cloud" within water-rich tissue. The rapid expansion and collapse of this bubble cloud precisely and selectively destroys and liquefies cancerous tissue. The destroyed cells are then excreted from the body as waste. A major advantage is the minimal damage to surrounding blood vessels and healthy tissue.Conventional treatments for liver cancer, such as surgery and radiofrequency ablation (RFA), have been the mainstream approaches. However, many patients have difficulty undergoing treatment due to factors such as impaired liver function, tumor location, complications, or advanced age. Histotripsy is gaining attention in Europe and the United States as a groundbreaking technology that offers a new treatment option for these patients.In Japan, histotripsy is currently approved to treat liver tumors, including hepatocellular carcinoma and metastatic liver cancer. However, it is expect...